272 related articles for article (PubMed ID: 29792149)
1. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y
J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Wu F; Jiang H; Zheng B; Kogiso M; Yao Y; Zhou C; Li XN; Song Y
J Med Chem; 2015 Sep; 58(17):6899-6908. PubMed ID: 26280302
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
8. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1.
Ma T; Zou F; Pusch S; Yang L; Zhu Q; Xu Y; Gu Y; von Deimling A; Zha X
Bioorg Med Chem; 2017 Dec; 25(24):6379-6387. PubMed ID: 29089260
[TBL] [Abstract][Full Text] [Related]
10. Discovery of linear unnatural peptides as potent mutant isocitrate dehydrogenase 1 inhibitors by Ugi reaction.
Zhou X; Zheng M; Zhao N; Hu Y; Yang K; Huo J; Liu G; Huang J; Chen L; Zhou Y; Li H
Bioorg Chem; 2022 Feb; 119():105569. PubMed ID: 34954572
[TBL] [Abstract][Full Text] [Related]
11. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
[TBL] [Abstract][Full Text] [Related]
12. 3-(7-Azaindolyl)-4-indolylmaleimides as a novel class of mutant isocitrate dehydrogenase-1 inhibitors: Design, synthesis, and biological evaluation.
Hu Y; Gao A; Liao H; Zhang M; Xu G; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
Arch Pharm (Weinheim); 2018 Oct; 351(10):e1800039. PubMed ID: 30113716
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration.
Cao H; Zhu G; Sun L; Chen G; Ma X; Luo X; Zhu J
Eur J Med Chem; 2019 Dec; 183():111694. PubMed ID: 31561044
[TBL] [Abstract][Full Text] [Related]
14. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
15. Discovery of α-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Kim HJ; Fei X; Cho SC; Choi BY; Ahn HC; Lee K; Seo SY; Keum YS
Bioorg Med Chem Lett; 2015 Dec; 25(23):5625-31. PubMed ID: 26508549
[TBL] [Abstract][Full Text] [Related]
16. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Fraser AR; Bacci B; le Chevoir MA; Long SN
J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Liu X; Hu Y; Gao A; Xu M; Gao L; Xu L; Zhou Y; Gao J; Ye Q; Li J
Bioorg Med Chem; 2019 Feb; 27(4):589-603. PubMed ID: 30600148
[TBL] [Abstract][Full Text] [Related]
18. Discovery of DC_H31 as potential mutant IDH1 inhibitor through NADPH-based high throughput screening.
Duan Z; Liu J; Niu L; Wang J; Feng M; Chen H; Luo C
Bioorg Med Chem; 2019 Aug; 27(15):3229-3236. PubMed ID: 31208797
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
[TBL] [Abstract][Full Text] [Related]
20. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
